Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7M2Drdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jrS2lEPTB;MD6wPFI{OSBizszNM1jKUXNCVkeHUh?=
SW756NHS4dFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\MTWM2OD1yLkG0NFI1KCEQvF2=MoXZV2FPT0WU
CTV-1M4e2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fSNGlEPTB;MD6xOlM6QCBizszNNUnQOoN[W0GQR1XS
HSC-4NEfWVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwMUexOVghKM7:TR?=MmfaV2FPT0WU
LAMA-84MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwMki2OlQhKM7:TR?=MXjTRW5ITVJ?
KU812MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTQTmlFUUN3ME2wMlM1ODZ6IDFOwG0>NELVR4lUSU6JRWK=
HCC1806NFHUfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHiTWM2OD1yLkO1NlE3KCEQvF2=M3vGTHNCVkeHUh?=
DOKM3;v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnu0TWM2OD1yLkO3O|g3KCEQvF2=NXjMO4hlW0GQR1XS
NCI-H209MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULzTW43UUN3ME2wMlQxQDB6IDFOwG0>NELZUoFUSU6JRWK=
EoL-1-cellMkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvWZnUxUUN3ME2wMlQyPTd4IDFOwG0>MUPTRW5ITVJ?
H9NIrOOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPpfXBbUUN3ME2wMlQ{PDZ2IDFOwG0>M1LOcnNCVkeHUh?=
EM-2NEjkcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILNWHNKSzVyPUCuOFM5QSBizszNMkj5V2FPT0WU
NCI-H292NV;uNGhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;VSYt[UUN3ME2wMlQ1OTB6IDFOwG0>NY\kflNzW0GQR1XS
697MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\2TWM2OD1yLkS1OlM{KCEQvF2=Mm\KV2FPT0WU
BHT-101NWnYW48xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHyTWM2OD1yLkS2OVkhKM7:TR?=MlnvV2FPT0WU
BE-13M1zWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2D4OWlEPTB;MD60PFU4OiBizszNM3e0N3NCVkeHUh?=
RS4-11NVXyZ5dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT6fYZKSzVyPUCuOFg2QDRiIN88US=>MXzTRW5ITVJ?
IGROV-1NUHESI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\rTWM2OD1yLkS4O|k4KCEQvF2=MlfYV2FPT0WU
KE-37NWrNdIE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwNEm1NFkhKM7:TR?=NXrofpd2W0GQR1XS
BV-173M2\QZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXITHdTUUN3ME2wMlUxPzl{IDFOwG0>MWnTRW5ITVJ?
MEG-01NX;2bZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvX[2ZEUUN3ME2wMlUyOjF2IDFOwG0>MX;TRW5ITVJ?
LB2241-RCCMkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTBwNUO3NVghKM7:TR?=NW\BcWVKW0GQR1XS
ACHNMmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVP5WoFQUUN3ME2wMlU1ODZ7IDFOwG0>M2G0[nNCVkeHUh?=
CTB-1Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXMN3ZKSzVyPUCuOVQ5OiBizszNNXjSOplmW0GQR1XS
HT-1080NWrZc4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjLTWM2OD1yLkW1N|Q6KCEQvF2=MYnTRW5ITVJ?
CHL-1NFzaSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoX1TWM2OD1yLkW1OFY2KCEQvF2=NXXrTm5qW0GQR1XS
EW-3M1fRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTBwNUW5N|UhKM7:TR?=NIHsNXlUSU6JRWK=
ES1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHYTWM2OD1yLk[3OFk5KCEQvF2=NIjUTGFUSU6JRWK=
KASUMI-1M{Wycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXJeXBIUUN3ME2wMlczOzNiIN88US=>MYHTRW5ITVJ?
SW13MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYCyNWFnUUN3ME2wMlc{Pzl6IDFOwG0>Mn\3V2FPT0WU
A3-KAWNY\GV2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXJTWM2OD1yLke5NlA5KCEQvF2=NX;tRlRJW0GQR1XS
LB771-HNCMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\OTWM2OD1yLkizNVA1KCEQvF2=MYjTRW5ITVJ?
OC-314M2DIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIS2N2JKSzVyPUCuPFY6PjViIN88US=>NXniVWpUW0GQR1XS
MLMAM3vvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTRSGFKSzVyPUCuPVA3PzViIN88US=>MWfTRW5ITVJ?
KARPAS-45MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwOUK0OlYhKM7:TR?=NF;nO49USU6JRWK=
CAL-27M2LQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkf6TWM2OD1yLkmyPVA3KCEQvF2=MnT2V2FPT0WU
SK-NEP-1M2HUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HhOmlEPTB;MD65O|I1QCBizszNMVLTRW5ITVJ?
COR-L105MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHYWHlKSzVyPUGuNFA{QTRiIN88US=>NEf0NGZUSU6JRWK=
TI-73MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvtOnpyUUN3ME2xMlAyPjViIN88US=>M4XyXXNCVkeHUh?=
JVM-3M3\IVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PVOWlEPTB;MT6wOVAyPyBizszNM4TRNXNCVkeHUh?=
HAL-01MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTFwMEi4NUAh|ryPNEPZd3RUSU6JRWK=
QIMR-WILM4DvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDhZnBKSzVyPUGuNFkxPThiIN88US=>MV3TRW5ITVJ?
HSC-3MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTFwMUG3PFMhKM7:TR?=Ml7yV2FPT0WU
KY821MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfsUowzUUN3ME2xMlE{OzVzIDFOwG0>MVrTRW5ITVJ?
5637NEf3NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1L6SmlEPTB;MT6xN|gxOyBizszNM3PjTHNCVkeHUh?=
CAL-33MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTFwMUmzNFIhKM7:TR?=M{LPeHNCVkeHUh?=
ES4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEO2XHBKSzVyPUGuNlA4QSBizszNMn;oV2FPT0WU
BHYMnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT0TWM2OD1zLkKyPFkzKCEQvF2=MVjTRW5ITVJ?
LB1047-RCCNX[yS|BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\P[mlEPTB;MT6yN|c5PSBizszNMVjTRW5ITVJ?
H4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnP5TWM2OD1zLkK0NlU2KCEQvF2=NH7lOI1USU6JRWK=
RPMI-8866MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTFwMk[xNFYhKM7:TR?=MnrpV2FPT0WU
HO-1-N-1M4H3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDycI1KSzVyPUGuNlY{PjliIN88US=>NFHoUopUSU6JRWK=
BB30-HNCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTFwMki3NVQhKM7:TR?=NHnvUlNUSU6JRWK=
PC-14NFLF[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnZTWM2OD1zLkK5NlA2KCEQvF2=M3[xRnNCVkeHUh?=
NUGC-3NYS4TYFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3IfJZpUUN3ME2xMlI6OzV4IDFOwG0>NH7XV25USU6JRWK=
A4-FukMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTKZ2tQUUN3ME2xMlMxPzB2IDFOwG0>M1zBbXNCVkeHUh?=
MHH-NB-11NEn6SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf2TWM2OD1zLkOxN|g{KCEQvF2=MnrRV2FPT0WU
KOSC-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvl[YpKSzVyPUGuN|E4PzViIN88US=>NHLYeJVUSU6JRWK=
A498NUH2NGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn4PGNpUUN3ME2xMlQxOTF|IDFOwG0>NWHKfYpWW0GQR1XS
KG-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MniyTWM2OD1zLkSxNlc{KCEQvF2=MYfTRW5ITVJ?
DELMnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nx[mlEPTB;MT60N|Y2PyBizszNM4m2TXNCVkeHUh?=
EW-16MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DvRmlEPTB;MT60N|k4OyBizszNMkTZV2FPT0WU
BPH-1M{TRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfTT|hzUUN3ME2xMlQ1QDB3IDFOwG0>MX\TRW5ITVJ?
JARMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTFwNEmzOkAh|ryPMnrBV2FPT0WU
J-RT3-T3-5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEX5VotKSzVyPUGuOVE4OjJiIN88US=>NY\6SGo1W0GQR1XS
A375M{i1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTFwNUG3O|IhKM7:TR?=NHLlTJpUSU6JRWK=
SW954M3LhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrvSWdKSzVyPUGuOVUxODdiIN88US=>MmTLV2FPT0WU
Ca9-22MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTFwNU[yOkAh|ryPNEHybItUSU6JRWK=
D-566MGNHL3O3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfiXo5KSzVyPUGuOVcyPTViIN88US=>MlmwV2FPT0WU
SCC-15MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTFwNkG4NFQhKM7:TR?=NYnYXIFSW0GQR1XS
HD-MY-ZNUXZRo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTFwNkO1PFQhKM7:TR?=NHvwUFhUSU6JRWK=
HT-1376NVXsToRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;nV5dKSzVyPUGuOlQ{PiBizszNNVXGNJJkW0GQR1XS
CAL-54M4mxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjWdpVwUUN3ME2xMlY2PzB7IDFOwG0>NIXQS49USU6JRWK=
ONS-76M2rNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlG1TWM2OD1zLk[3OVUyKCEQvF2=MV3TRW5ITVJ?
EFO-27M2TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTQRXhVUUN3ME2xMlY5QTJiIN88US=>MnLkV2FPT0WU
769-PMkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTFwNkm1PVYhKM7:TR?=NGCxPYlUSU6JRWK=
MV-4-11M3:4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XscmlEPTB;MT62PVg2PiBizszNMkDTV2FPT0WU
NKM-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjqeplKSzVyPUGuO|E5ODJiIN88US=>MmHkV2FPT0WU
LOXIMVIMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTFwN{S1PVkhKM7:TR?=MXvTRW5ITVJ?
KYSE-140MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnqzTWM2OD1zLke1OlU2KCEQvF2=MlnSV2FPT0WU
ES5Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\vNWlEPTB;MT64Olc1PyBizszNNFXxOI1USU6JRWK=
BB65-RCCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjuSldpUUN3ME2xMlg6QDR7IDFOwG0>NELRelhUSU6JRWK=
HNMkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFwOEm4O|QhKM7:TR?=M3jESnNCVkeHUh?=
A101DM{LKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLJTWM2OD1zLkmzOlI5KCEQvF2=Mor5V2FPT0WU
LoVoMnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFwOUe2O|khKM7:TR?=NHW4TZRUSU6JRWK=
NCI-H526M1nLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTJeI5tUUN3ME2xMlk6OzJ3IDFOwG0>MXjTRW5ITVJ?
NCI-H1693MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\sR|kzUUN3ME2xMlk6QDh6IDFOwG0>MkjkV2FPT0WU
OVCAR-4NYL4VHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:3OJp1UUN3ME2yMlAxPDN3IDFOwG0>MkDvV2FPT0WU
SK-HEP-1NVH4cZd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTJwMEC3OFUhKM7:TR?=M1PJenNCVkeHUh?=
C2BBe1NGG2UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3:zU2lEPTB;Mj6wN|M4OiBizszNNGfU[I9USU6JRWK=
MEL-JUSOMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTO[HNvUUN3ME2yMlA1PDZ2IDFOwG0>NXX3dmR6W0GQR1XS
MOLT-16MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnLTWM2OD1{LkC3NFU5KCEQvF2=NUK5XWg5W0GQR1XS
NBsusSRNWC3UndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPoWXNRUUN3ME2yMlA6QDh7IDFOwG0>NI\5UFlUSU6JRWK=
TK10M4PZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLhTWM2OD1{LkGzOFU5KCEQvF2=M{HaS3NCVkeHUh?=
CAL-39MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3yUmVSUUN3ME2yMlE1PDhiIN88US=>MX3TRW5ITVJ?
NCI-H2030NHH2TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP1VWFvUUN3ME2yMlE5QTd|IDFOwG0>NIXEd5ZUSU6JRWK=
HCT-116MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD1TWM2OD1{LkKyPVg1KCEQvF2=MmG3V2FPT0WU
HTC-C3M3ziVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTJwMk[4NlQhKM7:TR?=NEfUT|dUSU6JRWK=
TYK-nuMmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvFSlM6UUN3ME2yMlMxQTB7IDFOwG0>NFyzdJpUSU6JRWK=
FADUMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPJbJpKSzVyPUKuN|IzQTZiIN88US=>M1rBPXNCVkeHUh?=
A431NFzMSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\xVpNKSzVyPUKuN|cxOjViIN88US=>M2rEPXNCVkeHUh?=
TE-11NEDqeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTJwM{iwNVkhKM7:TR?=NXHLWXRMW0GQR1XS
CAL-12TMlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJwNEC0NVchKM7:TR?=NIjHcIdUSU6JRWK=
DBMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W5XGlEPTB;Mj60Nlg3QSBizszNNXy4SoFoW0GQR1XS
L-363MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTJwNEO1NFchKM7:TR?=Mmf2V2FPT0WU
MSTO-211HM3zuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnsTWM2OD1{Lk[2N|kyKCEQvF2=MmfVV2FPT0WU
SK-UT-1M2O5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7iW29KSzVyPUKuO|E1ODZiIN88US=>NWD6NXp6W0GQR1XS
RPMI-8226NUP4coN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTJwN{OxOlQhKM7:TR?=Moq1V2FPT0WU
SF295NEHHT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXleFJRUUN3ME2yMlc1OzFiIN88US=>M{HjO3NCVkeHUh?=
OS-RC-2NHnSTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTJwN{[2O|MhKM7:TR?=MnfOV2FPT0WU
SK-MEL-24MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LDXmlEPTB;Mj63PFIzPCBizszNMnjGV2FPT0WU
COR-L23M1e2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TLfWlEPTB;Mj63PVQ3PCBizszNNWj2SGF2W0GQR1XS
MHH-PREB-1M2TCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHETWM2OD1{LkiwNVYyKCEQvF2=MWrTRW5ITVJ?
SK-N-DZMmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJwOEG2N|ghKM7:TR?=M13ZZXNCVkeHUh?=
OMC-1NGPtOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXxTWM2OD1{Lki1NFA{KCEQvF2=NGXyWFJUSU6JRWK=
SK-MEL-2MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLVZZRsUUN3ME2yMlg6OjR|IDFOwG0>MVXTRW5ITVJ?
SASNVrCSHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTnTWM2OD1{Lkm5OFE2KCEQvF2=M4W0fHNCVkeHUh?=
EPLC-272HM4T5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XLV2lEPTB;Mz6wNFI{PSBizszNMYjTRW5ITVJ?
8505CM4L5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTNwMUCzNFEhKM7:TR?=MWfTRW5ITVJ?
EW-11M3TqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDGUG9KSzVyPUOuNVQzPzdiIN88US=>M2jpXHNCVkeHUh?=
YKG-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjTV4xvUUN3ME2zMlE1PzB4IDFOwG0>NUTLPXNOW0GQR1XS
EC-GI-10NHOxTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\aTWM2OD1|LkG3NlY{KCEQvF2=M2\URXNCVkeHUh?=
SK-LU-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3vVYpKSzVyPUOuNVg1OThiIN88US=>NEDJU3NUSU6JRWK=
P30-OHKMljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnvTWM2OD1|LkKwNVE4KCEQvF2=MU\TRW5ITVJ?
T-24MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLRZYg1UUN3ME2zMlIyQDF2IDFOwG0>NEfaRnVUSU6JRWK=
HSC-2NXTBR4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vJS2lEPTB;Mz6yNlI{OiBizszNMXzTRW5ITVJ?
SK-MES-1MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\2S2lEPTB;Mz6yOFgzQSBizszNNI[4UJhUSU6JRWK=
SW48NWHCXIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fMRmlEPTB;Mz6yOVQ5PiBizszNNXvs[GhnW0GQR1XS
ME-180Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTNwMk[wOVEhKM7:TR?=NYXoUmRVW0GQR1XS
NCI-H2009NHHBblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfaN4VKSzVyPUOuNlkxOSBizszNM1m2VHNCVkeHUh?=
HL-60MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkmxTWM2OD1|LkK5NVMhKM7:TR?=NGTi[VlUSU6JRWK=
NCI-N87MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLZTWM2OD1|LkOwNVczKCEQvF2=MVXTRW5ITVJ?
GMS-10MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTNwM{SwPFYhKM7:TR?=MnjmV2FPT0WU
SCHNHWyN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3uxb2lEPTB;Mz60NFg1PCBizszNNWTHO4hOW0GQR1XS
C-33-AMkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF:wWolKSzVyPUOuOFE1OjFiIN88US=>NULsU21NW0GQR1XS
NCI-H1703MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTNwNEG4NVIhKM7:TR?=NX7qcWhMW0GQR1XS
A427NWD2eYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwNE[xNlQhKM7:TR?=NG[5bWNUSU6JRWK=
MOLT-4MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTNwNEixPVkhKM7:TR?=NHOxbItUSU6JRWK=
NCI-H1792MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjVbGRiUUN3ME2zMlQ6QDB{IDFOwG0>MYHTRW5ITVJ?
NCI-H1650MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTNwNUeyPUAh|ryPMYPTRW5ITVJ?
H-EMC-SSNX7GN4lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn:yTWM2OD1|LkW4OVY6KCEQvF2=MXXTRW5ITVJ?
SW982NH7OSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nwdmlEPTB;Mz61PFgzQSBizszNNHrVNoZUSU6JRWK=
DSH1NXm2ZZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2K4TmlEPTB;Mz62OFEzOiBizszNMYnTRW5ITVJ?
NOS-1NFf4SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX76TmJ[UUN3ME2zMlY1Ojd4IDFOwG0>Ml3TV2FPT0WU
BT-549NGjJdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHUTWM2OD1|Lk[3PFU1KCEQvF2=M{nEe3NCVkeHUh?=
HuCCT1NFKzb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLNb|RKSzVyPUOuO|QyPzdiIN88US=>MlPwV2FPT0WU
NCI-H1755MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M130XmlEPTB;Mz65Olk4OSBizszNNYLkWW9OW0GQR1XS
KYSE-450MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFO3WoFKSzVyPUOuPVY6QTdiIN88US=>MV7TRW5ITVJ?
MIA-PaCa-2Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTNwOUeyPUAh|ryPNWfRXnA5W0GQR1XS
U-266NEP4RotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVix[2hbUUN3ME2zMlk4PDhzIDFOwG0>NXO0TG9uW0GQR1XS
MewoM1H6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTRwME[zOlEhKM7:TR?=M{PqeXNCVkeHUh?=
KYSE-520M1ixOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTRwMEm3PVkhKM7:TR?=M4flXXNCVkeHUh?=
MN-60NIfpOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvDW2JKSzVyPUSuNVA2ODFiIN88US=>MUTTRW5ITVJ?
Ramos-2G6-4C10NYG5XGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\oTWM2OD12LkG2O|M6KCEQvF2=NVzkR4l5W0GQR1XS
SK-MEL-1NW[3TGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTRwMUi2PVUhKM7:TR?=M3nXcnNCVkeHUh?=
ABC-1NYfUd5JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zHSGlEPTB;ND6yN|M{OyBizszNNY[4bIIxW0GQR1XS
CAKI-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPwS|dKSzVyPUSuNlQ2PzFiIN88US=>NIHDWXFUSU6JRWK=
HOSNXnpb3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTRwMkmxOFEhKM7:TR?=MmK1V2FPT0WU
SN12CMknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnL6TWM2OD12LkO0NlQ1KCEQvF2=M3PWVHNCVkeHUh?=
NB13M3T1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrMcVhYUUN3ME20MlM4OzV3IDFOwG0>M2fKXHNCVkeHUh?=
M14MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fDVWlEPTB;ND60PFc6OiBizszNM3PUOnNCVkeHUh?=
GP5dMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HkbGlEPTB;ND61NFEzKCEQvF2=NWDLRZA1W0GQR1XS
NCI-H720NYTWU|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfxTWxTUUN3ME20MlU{PjF{IDFOwG0>NFHGVZJUSU6JRWK=
D-423MGMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2P0N2lEPTB;ND61N|kzPCBizszNM1n3eHNCVkeHUh?=
ChaGo-K-1NGfDWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLNfGI3UUN3ME20MlU6PTV7IDFOwG0>M3\3NXNCVkeHUh?=
MEL-HOMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTRwNkGyOlEhKM7:TR?=MUXTRW5ITVJ?
MHH-ES-1M1KzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTRwNkK0NVEhKM7:TR?=MkfmV2FPT0WU
KYSE-270MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\iTWM2OD12Lk[1NVI3KCEQvF2=Ml7lV2FPT0WU
GI-ME-NNHuy[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3KWW1KSzVyPUSuO|EzQTFiIN88US=>M{fDTHNCVkeHUh?=
HOP-92NXPBNW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXaTWM2OD12LkixN|c6KCEQvF2=MUXTRW5ITVJ?
MKN1NX3qOZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HZbWlEPTB;ND64N|kyPCBizszNMlLwV2FPT0WU
ML-2NGfSVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXoTWM2OD12Lki1OlI3KCEQvF2=NW[0V2k6W0GQR1XS
RO82-W-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTRwOUK5PEAh|ryPMUfTRW5ITVJ?
G-361NIPQWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPL[YNKSzVyPUWuNFExODNiIN88US=>NHrLOGlUSU6JRWK=
HC-1NGT2b3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoL2TWM2OD13LkCzNlkyKCEQvF2=MmTWV2FPT0WU
EW-24MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUn1cYRvUUN3ME21MlA1ODN6IDFOwG0>NXr2UFU5W0GQR1XS
HuP-T4NYnZfIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;lN2lEPTB;NT6xOFM{PCBizszNNE\G[VBUSU6JRWK=
8-MG-BAMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rpZWlEPTB;NT6zOFI5KCEQvF2=MUHTRW5ITVJ?
HGC-27NWruU3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXiRnc6UUN3ME21MlM4Pjh{IDFOwG0>NG\WNXVUSU6JRWK=
TE-12NYrHeXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTVwNEG1PFUhKM7:TR?=MljIV2FPT0WU
GT3TKBNG\3cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTVwNESyNVIhKM7:TR?=M1\RNXNCVkeHUh?=
DOHH-2MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjBOHpUUUN3ME21MlQ2QTh4IDFOwG0>NFnmN4dUSU6JRWK=
Ca-SkiMmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYqxO|dmUUN3ME21MlQ3OTF3IDFOwG0>NIf6WXVUSU6JRWK=
A172MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnPNGRNUUN3ME21MlU1QTJ3IDFOwG0>M1jYUnNCVkeHUh?=
EGI-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrvNWF{UUN3ME21MlU5QTN6IDFOwG0>M3;vOXNCVkeHUh?=
MZ2-MELMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTVwNkG0PFYhKM7:TR?=M2rKfXNCVkeHUh?=
SW1710NGTWbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfQSWhKSzVyPUWuOlkxQTFiIN88US=>NY\rT5J1W0GQR1XS
HT-144MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX6zOIdiUUN3ME21MlczPjh3IDFOwG0>MV3TRW5ITVJ?
PA-1MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT4TWM2OD13LkixPFk{KCEQvF2=MkXWV2FPT0WU
HCC1937MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjiO2N{UUN3ME21Mlg{QTJ7IDFOwG0>MmSzV2FPT0WU
SK-OV-3M4Xqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvsOIlKSzVyPUWuPVEyOjFiIN88US=>NGfkbYlUSU6JRWK=
K5NYnDXYNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mon1TWM2OD14LkC1NVchKM7:TR?=NHjEbpJUSU6JRWK=
NMC-G1NIfEWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr1c2tmUUN3ME22MlA4Pzl5IDFOwG0>NILSPWhUSU6JRWK=
MDA-MB-361MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXBZphKUUN3ME22MlA6OjZzIDFOwG0>Mn3XV2FPT0WU
EKVXMmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEO2bIdKSzVyPU[uNVM2ODFiIN88US=>M3vUNnNCVkeHUh?=
ES7MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3TeWwxUUN3ME22MlE3OTF3IDFOwG0>M3vqN3NCVkeHUh?=
KS-1M4mzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVKyflBQUUN3ME22MlE4QTl|IDFOwG0>M{DSN3NCVkeHUh?=
NCI-H661NFOyNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{OwTGlEPTB;Nj6xPFA5OSBizszNNX\zUodoW0GQR1XS
ES8NUjk[INuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHGdXdKSzVyPU[uNVgxQDJiIN88US=>NEjOV4tUSU6JRWK=
NCI-H23MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\4e|hKSzVyPU[uNlE5OTZiIN88US=>Ml7pV2FPT0WU
T47DMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\hVGZKSzVyPU[uNlY1PTdiIN88US=>MlrOV2FPT0WU
A2780NYDNcnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfzZ|ZKSzVyPU[uN|c4ODFiIN88US=>M2\NVXNCVkeHUh?=
SCC-4M1TpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjlU|NKSzVyPU[uOFM2PjFiIN88US=>MoLPV2FPT0WU
VA-ES-BJMljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHxTWM2OD14Lkm3NFQ{KCEQvF2=M1vRWnNCVkeHUh?=
no-11M3rvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTdwMU[0NUAh|ryPMUTTRW5ITVJ?
KU-19-19MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTdwMU[0O|YhKM7:TR?=MUfTRW5ITVJ?
MKN45NVzkTZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLkVWNPUUN3ME23MlE5Pjl7IDFOwG0>M3rT[nNCVkeHUh?=
SCC-25MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrrWpRKSzVyPUeuNlM1OTRiIN88US=>M1LnUHNCVkeHUh?=
ETK-1MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfRTWM2OD15LkK1OVE1KCEQvF2=MYnTRW5ITVJ?
COR-L88NY\LN4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDpUVU1UUN3ME23MlI6OzF7IDFOwG0>M1PnW3NCVkeHUh?=
8305CNHrTT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu4SXJ4UUN3ME23MlMzPDl{IDFOwG0>NXvsN2JSW0GQR1XS
Detroit562MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vPNmlEPTB;Nz6zNlUxPiBizszNM1nKRXNCVkeHUh?=
SNU-449NYPMSWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XRNWlEPTB;Nz6zO|Y2OSBizszNMon1V2FPT0WU
A704MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrEfJM1UUN3ME23MlM5Ojd6IDFOwG0>NWHXV4JMW0GQR1XS
D-502MGMlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTdwM{i0O|MhKM7:TR?=M2jqPHNCVkeHUh?=
NCI-H2228NIPpV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PzU2lEPTB;Nz60NVQ2QCBizszNNUPQb5AxW0GQR1XS
CHP-212NI\neFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XqUmlEPTB;Nz61NVg6PiBizszNMlL6V2FPT0WU
VMRC-RCZMnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mki4TWM2OD15LkW5NFY3KCEQvF2=MXnTRW5ITVJ?
RPMI-2650MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTdwN{CzNVIhKM7:TR?=Mmq3V2FPT0WU
HCC2218M4\wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrpZpd[UUN3ME23MlczOjV6IDFOwG0>M2\6SHNCVkeHUh?=
GCTNI\WcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTdwOEKxO|IhKM7:TR?=NWrpbmtbW0GQR1XS
SW780Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTIUoIzUUN3ME23Mlk6ODZiIN88US=>MlzIV2FPT0WU
KMOE-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{SzU2lEPTB;OD6wOFA4KCEQvF2=M1PZenNCVkeHUh?=
KYSE-180MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnP5TWM2OD16LkC4OlQ5KCEQvF2=Ml7zV2FPT0WU
TE-1M{fy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHKTWM2OD16LkGxNFU4KCEQvF2=M{\Tc3NCVkeHUh?=
OAW-42NHW0e21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DFVGlEPTB;OD6yOVQ6PiBizszNMY\TRW5ITVJ?
VM-CUB-1MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYq2NHBnUUN3ME24MlI5OzZ2IDFOwG0>M2XVcnNCVkeHUh?=
ECC10NYTYbJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTue3hvUUN3ME24MlI5Ozl5IDFOwG0>NUDidXRnW0GQR1XS
SW1573NX;3OYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRThwNES0OlUhKM7:TR?=MVLTRW5ITVJ?
NCI-H1299M1mxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PYeWlEPTB;OD61PVc4PCBizszNM{TkTHNCVkeHUh?=
ALL-POMoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PUTmlEPTB;OD62OlU6PyBizszNMVnTRW5ITVJ?
OVCAR-5M4XYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRThwN{e2NlUhKM7:TR?=MYHTRW5ITVJ?
NCI-SNU-5MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrYTmF7UUN3ME24Mlg{ODBzIDFOwG0>MYTTRW5ITVJ?
NCI-H2342MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF35[nRKSzVyPUiuPFMyODFiIN88US=>NX3F[3dyW0GQR1XS
RPMI-7951NVj4OGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXZWG1CUUN3ME24Mlg1OTV5IDFOwG0>MUHTRW5ITVJ?
RCM-1NHjVcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTlwMEixOFUhKM7:TR?=NYHESlhMW0GQR1XS
DaoyMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTlwMUKwNlghKM7:TR?=NXPr[WFsW0GQR1XS
HCC1395NYPHNHpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPkXW9KSzVyPUmuN|A5QTZiIN88US=>MkTJV2FPT0WU
786-0NYDFfWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnrTWM2OD17LkO2NFI3KCEQvF2=MXzTRW5ITVJ?
GAMGNEXWNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X4d2lEPTB;OT62OVU{PCBizszNMXLTRW5ITVJ?
HCC1954NGe3bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37lXmlEPTB;OT64OVg2QSBizszNM4j4cHNCVkeHUh?=
NCI-H1838MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjhOZR5UUN3ME25MlkxOzdzIDFOwG0>Mny4V2FPT0WU
SW620MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1n5fGlEPTB;OT65OVM2PyBizszNNH;JWItUSU6JRWK=
NCI-H358NVn2NI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTFyLkSxPVchKM7:TR?=NXW3T28zW0GQR1XS
NCI-H1793MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTFyLkSyOFghKM7:TR?=MlL0V2FPT0WU
NCI-H1666MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\lc2lEPTB;MUCuOFM2PSBizszNM2[zdnNCVkeHUh?=
MZ7-melNX7PUlZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTxWWVVUUN3ME2xNE41PzV|IDFOwG0>M3vJdHNCVkeHUh?=
MDA-MB-175-VIIMni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3T4W2lEPTB;MUCuOlM6PiBizszNMlixV2FPT0WU
COLO-829NE\3VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rq[2lEPTB;MUCuPFAxPCBizszNM3nrcXNCVkeHUh?=
RVH-421M3HIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7kb|NKSzVyPUGxMlE2OiBizszNNFrF[pVUSU6JRWK=
A549MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrETWM2OD1zMT6yOFc5KCEQvF2=M3TI[3NCVkeHUh?=
DJM-1MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Lz[WlEPTB;MUGuN|g{OyBizszNMYPTRW5ITVJ?
IST-MEL1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjuPXVzUUN3ME2xNU44OzF7IDFOwG0>NIPtVmtUSU6JRWK=
BENNHLOVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnP1TWM2OD1zMT63OFAzKCEQvF2=M1W0RnNCVkeHUh?=
KM12M3vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrxTWM2OD1zMT65NFkyKCEQvF2=NV;pfFJXW0GQR1XS
HuO9MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTuTWM2OD1zMj6wOlY3KCEQvF2=NFX2TGxUSU6JRWK=
U-2-OSNIHTbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3MTWM2OD1zMj6wPFk{KCEQvF2=NELrNHRUSU6JRWK=
RH-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTF{LkS0O|IhKM7:TR?=NXjCPYFHW0GQR1XS
NCI-H1048MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\WZWlUUUN3ME2xNk42PTB4IDFOwG0>MmP1V2FPT0WU
Mo-TMonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFm1dlhKSzVyPUGyMlc{ODdiIN88US=>NXfuRo9CW0GQR1XS
KYSE-150MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vibGlEPTB;MUKuO|Q2PSBizszNNV:5NmY{W0GQR1XS
A388NVfiSIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LqfWlEPTB;MUKuO|cyOyBizszNNFXsVJdUSU6JRWK=
NCI-SNU-1NFvqWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnP0TWM2OD1zMj64NFQ3KCEQvF2=M3vCT3NCVkeHUh?=
HELMnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjlSplpUUN3ME2xNk45OjF{IDFOwG0>NEjoT2pUSU6JRWK=
UM-UC-3NVzBPWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF{Lki4O|QhKM7:TR?=NWnofll7W0GQR1XS
TGBC24TKBNUG0bJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIf6cnBKSzVyPUGzMlAzPjdiIN88US=>NFTPS4VUSU6JRWK=
SW626M17wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\DWmdKSzVyPUGzMlI1QDViIN88US=>MmWyV2FPT0WU
ES6NF;MWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTF|LkK1NVIhKM7:TR?=M3LXfXNCVkeHUh?=
NCI-H2029MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rEfGlEPTB;MUOuPFExQCBizszNM1z1V3NCVkeHUh?=
RXF393NHTkN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\3UJJKSzVyPUGzMlk6OjdiIN88US=>Mn6zV2FPT0WU
HMV-IIMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M16z[GlEPTB;MUSuNFc5KCEQvF2=Mo\3V2FPT0WU
EW-22NHrkcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTF2LkG1NFIhKM7:TR?=M{PMd3NCVkeHUh?=
AsPC-1M3XLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPuelh2UUN3ME2xOE42PjRiIN88US=>NX\5UnJTW0GQR1XS
COLO-678NUX3PI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jhOGlEPTB;MUSuO|I4OSBizszNNUXXTplwW0GQR1XS
HCT-15M1LyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3f4R2lEPTB;MUSuPFg2PSBizszNMXXTRW5ITVJ?
HCE-TM{TUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDGS5VUUUN3ME2xOE45QDd2IDFOwG0>NEnUVZdUSU6JRWK=
SF539MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTF3LkC2OFMhKM7:TR?=MkewV2FPT0WU
AU565M2Ph[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LZTmlEPTB;MUWuNlA6PiBizszNMk[4V2FPT0WU
JVM-2MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{j3XWlEPTB;MUWuNlY5OSBizszNM{HEc3NCVkeHUh?=
CaR-1NWfU[|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPnTWM2OD1zNT60OFEzKCEQvF2=M4\FfHNCVkeHUh?=
23132-87MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHDO2lCUUN3ME2xOU45PDl3IDFOwG0>NGf5boFUSU6JRWK=
A673NFTPfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nSZWlEPTB;MUWuPVY{PiBizszNNUHlXIpmW0GQR1XS
KYSE-410MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF4LkCyPUAh|ryPMoLrV2FPT0WU
TE-9NHr4NYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTF4LkC2NkAh|ryPNWPvendjW0GQR1XS
LU-139NX7o[VRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mon2TWM2OD1zNj6xPFI{KCEQvF2=NXz1S|JoW0GQR1XS
GCIYM3LwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDQT|ZKSzVyPUG2MlE6OTZiIN88US=>NYD1O5B{W0GQR1XS
JEG-3MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPNdIhKSzVyPUG2MlI2KCEQvF2=MYXTRW5ITVJ?
RT-112M{TWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV72[ldoUUN3ME2xOk41OTR|IDFOwG0>NWTTN5RpW0GQR1XS
COLO-680NNYnlTmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHW0foNKSzVyPUG2MlUyODhiIN88US=>MXjTRW5ITVJ?
LU-134-AM2CyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn3TFRKSzVyPUG2Mlk5QTNiIN88US=>NX;HeZNLW0GQR1XS
MFM-223Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXiyPFJPUUN3ME2xO{4yPTN3IDFOwG0>MmHLV2FPT0WU
SF126MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTF5LkG3NFEhKM7:TR?=MoSxV2FPT0WU
NCI-H28NFzyVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojoTWM2OD1zNz6yNFY3KCEQvF2=M1WwPXNCVkeHUh?=
BFTC-905MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVO2Olg{UUN3ME2xO{41QDN{IDFOwG0>M4nBOXNCVkeHUh?=
SCC-9M3fYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvSZoVtUUN3ME2xO{43Ojh3IDFOwG0>MnzuV2FPT0WU
KNS-62M1[0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYflWVByUUN3ME2xO{43PjJ7IDFOwG0>NHTWOZRUSU6JRWK=
Hs-578-TNVHaRmVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPqPYlKSzVyPUG3MlgyPDliIN88US=>NYPtOXBnW0GQR1XS
D-336MGMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTF5LkiyPVQhKM7:TR?=MXTTRW5ITVJ?
NCI-H82NVPwTVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTlSZBKSzVyPUG4MlAyQDNiIN88US=>NFr1UZFUSU6JRWK=
EFM-19NYfvSWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nvNWlEPTB;MUiuNFU4PyBizszNMmC3V2FPT0WU
TGBC11TKBMlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PVXWlEPTB;MUiuNVAzOSBizszNM1zIbXNCVkeHUh?=
HEC-1M2q3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF6LkK5NVghKM7:TR?=NYjiT2lVW0GQR1XS
HuP-T3M1rDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1z4Z2lEPTB;MUiuOVkzQSBizszNNXrOOJFjW0GQR1XS
SF268M3vKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF6Lk[3NFIhKM7:TR?=NUDL[WQ3W0GQR1XS
COLO-792MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTkTWM2OD1zOD63PVk4KCEQvF2=M2WwWHNCVkeHUh?=
HLEM2C1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\vTWM2OD1zOD64N|MyKCEQvF2=M{\GTHNCVkeHUh?=
A204NXXkTFBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPjTWM2OD1zOD65NVY1KCEQvF2=MoPWV2FPT0WU
CAL-72MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjKdIFKSzVyPUG5MlA5PzdiIN88US=>NXHUe3JFW0GQR1XS
U031NFzPRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[wV4ViUUN3ME2xPU41QTB7IDFOwG0>NEn0NlFUSU6JRWK=
FTC-133NWPDTo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTF7LkmzNFQhKM7:TR?=NIfJ[IhUSU6JRWK=
SK-MEL-28NHToRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTJyLkO3OlEhKM7:TR?=NWHSOJU6W0GQR1XS
KGNNFT6PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fFTGlEPTB;MkCuOFY6QSBizszNNYnmcol[W0GQR1XS
HCC2998MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnuzTWM2OD1{MT6zPVI3KCEQvF2=NILmSI5USU6JRWK=
GOTONVLzVpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PEeWlEPTB;MkGuOFg2KCEQvF2=NWXmWWRVW0GQR1XS
AGSMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJzLki0OVEhKM7:TR?=M2\LOnNCVkeHUh?=
EW-13MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJ{LkGwNlIhKM7:TR?=NHrE[GNUSU6JRWK=
P12-ICHIKAWAMkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTtTWM2OD1{Mj6xOlA{KCEQvF2=NIXCdnRUSU6JRWK=
NCI-H1395NH20cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7vb2FWUUN3ME2yNk4zQTB5IDFOwG0>MkHIV2FPT0WU
A2058MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M172fGlEPTB;MkKuOFM1KCEQvF2=M{DVO3NCVkeHUh?=
SH-4NYXBZZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3BfIxCUUN3ME2yNk44ODR3IDFOwG0>M1nj[nNCVkeHUh?=
DoTc2-4510NHTUR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi1TWM2OD1{Mz62OFczKCEQvF2=NUfVd|JHW0GQR1XS
MMAC-SFMmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo[5TWM2OD1{Mz62PVEyKCEQvF2=M2LlNXNCVkeHUh?=
NCI-H510ANUnERmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\VemlEPTB;MkOuO|k{QSBizszNMoPWV2FPT0WU
HDLM-2M2nze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\UU2hKSzVyPUK0MlE1PiBizszNMlvsV2FPT0WU
KINGS-1MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLrTWM2OD1{ND6yOFIhKM7:TR?=Mln2V2FPT0WU
NCI-H1648NGjnUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jJdmlEPTB;MkSuOFAzPCBizszNNWnoWY9GW0GQR1XS
HCC1187MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJ3LkCyN|UhKM7:TR?=NXvSU5JrW0GQR1XS
BALL-1NGrEdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrRTWM2OD1{NT6yNFYzKCEQvF2=NGPRPGRUSU6JRWK=
SBC-1NEjneZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTJ3LkK5PVMhKM7:TR?=MYjTRW5ITVJ?
BFTC-909M{f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnsOWNMUUN3ME2yOU4{PTVzIDFOwG0>NUXpR3R4W0GQR1XS
MOLT-13M4XvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zzXWlEPTB;MkWuOlc1PCBizszNM{S0cXNCVkeHUh?=
SW1990NYrSTYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjxTWM2OD1{NT65OlU2KCEQvF2=Mkf6V2FPT0WU
DK-MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\5[mlEPTB;Mk[uNFQ1OyBizszNM2L3TnNCVkeHUh?=
TE-8M4HpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXiTGZKSzVyPUK2MlA3PjhiIN88US=>NH\hZ5RUSU6JRWK=
BeckerNYPiUFZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLhbJFKSzVyPUK2MlE2PzRiIN88US=>MoPLV2FPT0WU
KYSE-70MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLMWZp{UUN3ME2yOk42OzF5IDFOwG0>NHHrSnBUSU6JRWK=
MKN7MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTJ5Lke0O|khKM7:TR?=NIrIZVRUSU6JRWK=
D-392MGNEHCRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7rWHYzUUN3ME2yO{44Pjl2IDFOwG0>MUjTRW5ITVJ?
NH-12MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXHe45nUUN3ME2yPE4yOjJ7IDFOwG0>NYHO[25GW0GQR1XS
EW-18MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7yPXQ{UUN3ME2yPE4zOjF6IDFOwG0>MXTTRW5ITVJ?
LCLC-97TM1MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJ6LkK3OlIhKM7:TR?=MkTkV2FPT0WU
NCI-H1770MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofsTWM2OD1{OD6zOVY3KCEQvF2=MYPTRW5ITVJ?
BT-20M2m1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXYTWM2OD1{OD6zOlg2KCEQvF2=MWjTRW5ITVJ?
DBTRG-05MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nsW2lEPTB;MkiuOFg{QCBizszNMVHTRW5ITVJ?
HPAF-IIMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfZN4pEUUN3ME2yPE44PzliIN88US=>NX7kdYlqW0GQR1XS
SW837MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TINWlEPTB;MkmuN|M5PSBizszNNWH6[5hIW0GQR1XS
647-VNWHER5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLIV4xKSzVyPUK5MlcxODNiIN88US=>M2O3dnNCVkeHUh?=
J82MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDaO25nUUN3ME2yPU45ODF|IDFOwG0>MYfTRW5ITVJ?
MC116M1XXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIC1VldKSzVyPUOwMlA4OzNiIN88US=>MVPTRW5ITVJ?
NCI-H69M1TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfKZZBQUUN3ME2zNE43ODl|IDFOwG0>NVLqZnBsW0GQR1XS
NB6NG\DTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDYe4g3UUN3ME2zNU4{PjJ7IDFOwG0>NFvqeJVUSU6JRWK=
CAL-120MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Tyd2lEPTB;M{KuOFMyPyBizszNMnzhV2FPT0WU
U-87-MGMkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTN|LkCyOVEhKM7:TR?=NESxdGNUSU6JRWK=
NCI-H1304MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;sVm1KSzVyPUOzMlA{PTRiIN88US=>M4LLcnNCVkeHUh?=
YH-13NEHtZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXZT5ZKSzVyPUOzMlI2OzViIN88US=>NUnIT2c{W0GQR1XS
RMG-IMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPzTpdPUUN3ME2zN{41Ojh3IDFOwG0>MX;TRW5ITVJ?
LU-65MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvlRlJKSzVyPUO0MlE1ODhiIN88US=>NYnDWmFpW0GQR1XS
GB-1Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDDNYNKSzVyPUO1MlA4OjliIN88US=>NETiOlJUSU6JRWK=
DU-4475M13NSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTN3LkG1OVMhKM7:TR?=M4fy[nNCVkeHUh?=
SBC-5M1jQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnxO5hSUUN3ME2zOk42QTB{IDFOwG0>M{PsN3NCVkeHUh?=
OE33NGrMUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\0U2lEPTB;M{euO|U4PyBizszNMW\TRW5ITVJ?
C8166M3\mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTN6LkWyOlchKM7:TR?=MljTV2FPT0WU
COLO-684MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTN6Lke0NlghKM7:TR?=NWH4Z5pmW0GQR1XS
NCI-H1155MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3hcnZKSzVyPUO5MlA1PzFiIN88US=>NV\tW3JNW0GQR1XS
ATN-1NVzXPINCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPHTWM2OD1|OT63O|kzKCEQvF2=NV7WUolRW0GQR1XS
KARPAS-299NVTQbpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1z1T2lEPTB;M{muPFM6KCEQvF2=NG\PTYxUSU6JRWK=
KNS-81-FDM{fNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfsbGcyUUN3ME20NE4{PjB2IDFOwG0>Mlq4V2FPT0WU
NCI-H1563M3jCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvFTWM2OD12MT61NFM6KCEQvF2=MlTkV2FPT0WU
NB14MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTwcIdTUUN3ME20Nk44OjZ|IDFOwG0>NWXvTox4W0GQR1XS
COLO-800M3\FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzoU|dlUUN3ME20Nk45PTF5IDFOwG0>M3jp[XNCVkeHUh?=
MS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHUTWM2OD12Mz6wOFg{KCEQvF2=MUHTRW5ITVJ?
OVCAR-8M{Lhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPidId3UUN3ME20N{43QDB7IDFOwG0>Mk\CV2FPT0WU
SK-PN-DWNIX2XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTR|Lki3O|YhKM7:TR?=M3LKXHNCVkeHUh?=
G-402M{Xq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rVVWlEPTB;NEOuPVAxPiBizszNM2nuO3NCVkeHUh?=
NCI-H2291NFTTV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TxRWlEPTB;NESuPFAyPyBizszNNX7ObXkzW0GQR1XS
PC-3NXHoV5R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTR3LkiwNlMhKM7:TR?=M2TxcHNCVkeHUh?=
NCI-H1581M3TkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTBOm9pUUN3ME20OU46QDh7IDFOwG0>M1\VdnNCVkeHUh?=
SW1116M{HYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mly5TWM2OD12Nz6wNVgzKCEQvF2=M4nJb3NCVkeHUh?=
ZR-75-30Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qzc2lEPTB;NEeuNFI{QSBizszNMXzTRW5ITVJ?
OCI-AML2NVXQbXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTR5LkC5NVghKM7:TR?=NHTReFZUSU6JRWK=
MDA-MB-231NGTROHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvzVXlKSzVyPUS3MlYzPDliIN88US=>M4HjSnNCVkeHUh?=
ES3M{\mOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj3VJl1UUN3ME20PE4{PTJ7IDFOwG0>MmGzV2FPT0WU
NCI-H630MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn74TWM2OD12OT6xO|QzKCEQvF2=MVLTRW5ITVJ?
OE19MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\KTWM2OD12OT6yPVAzKCEQvF2=M3XuUHNCVkeHUh?=
NCI-H1573NV;pelFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTR7Lk[4OlEhKM7:TR?=NYDDO3d1W0GQR1XS
EW-1NG\VUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDHTWM2OD12OT65NFg1KCEQvF2=NUPuN3dqW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation(3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us